acc2401 |
STAT6 |
phosphorylation |
Tyr641 |
human |
Breast Cancer |
EO771 |
Emodin |
Associated |
4.0 (Moderate) |
25311112
|
acc2402 |
H2AX |
methylation |
Lys134 |
human |
Breast Cancer |
MDA-MB-231 |
Doxorubicin |
Impairing |
4.5 (High)
|
30159125
|
acc2403 |
H2AX |
phosphorylation |
Ser139 |
human |
Breast Cancer |
MDA-MB-231 |
Doxorubicin |
Impairing |
4.5 (High)
|
30159125
|
acc2404 |
H2AX |
methylation |
Lys134 |
human |
Lung Cancer |
A549 |
Doxorubicin |
Impairing |
4.5 (High)
|
30159125
|
acc2405 |
H2AX |
phosphorylation |
Ser139 |
human |
Lung Cancer |
A549 |
Doxorubicin |
Impairing |
4.5 (High)
|
30159125
|
acc2406 |
H2AX |
methylation |
Lys134 |
human |
Breast Cancer |
MDA-MB-231 |
OTS193320 |
Associated |
3.0 (Low)
|
30159125
|
acc2407 |
H2AX |
phosphorylation |
Ser139 |
human |
Breast Cancer |
MDA-MB-231 |
OTS193320 |
Associated |
3.0 (Low)
|
30159125
|
acc2408 |
H2AX |
methylation |
Lys134 |
human |
Lung Cancer |
A549 |
OTS193320 |
Associated |
3.0 (Low)
|
30159125
|
acc2409 |
H2AX |
phosphorylation |
Ser139 |
human |
Lung Cancer |
A549 |
OTS193320 |
Associated |
3.0 (Low)
|
30159125
|
acc2410 |
YAP |
phosphorylation |
Ser127 |
human |
Pancreas Cancer |
PANC-1 |
Gemcitabine |
Impairing |
5.0 (High)
|
31627466
|
acc2411 |
YAP |
phosphorylation |
Ser127 |
human |
Pancreas Cancer |
BxPC-3 |
Gemcitabine |
Impairing |
5.0 (High)
|
31627466
|
acc2412 |
YAP |
phosphorylation |
Ser127 |
human |
Pancreas Cancer |
ASPC-1 |
Gemcitabine |
Impairing |
5.0 (High)
|
31627466
|
acc2413 |
Bcl-2 |
phosphorylation |
unclear |
human |
Lung Cancer |
H5800 |
Cisplatin |
Enhancing |
5.0 (High)
|
24548862
|
acc2414 |
Bcl-2 |
phosphorylation |
unclear |
mouse |
Lung Cancer |
LKR |
Cisplatin |
Enhancing |
5.0 (High)
|
24548862
|
acc2415 |
Beclin-1 |
ubiquitination |
Ser90 |
human |
Myeloma |
KMS11 |
BTZ |
Impairing |
5.0 (High)
|
31955515
|
acc2416 |
Beclin-1 |
ubiquitination |
Ser90 |
human |
Myeloma |
RPMI8226 |
BTZ |
Impairing |
5.0 (High)
|
31955515
|
acc2417 |
Beclin-1 |
ubiquitination |
Ser93 |
human |
Myeloma |
KMS11 |
BTZ |
Impairing |
5.0 (High)
|
31955515
|
acc2418 |
Beclin-1 |
ubiquitination |
Ser93 |
human |
Myeloma |
RPMI8226 |
BTZ |
Impairing |
5.0 (High)
|
31955515
|
acc2419 |
Beclin-1 |
ubiquitination |
Ser96 |
human |
Myeloma |
KMS11 |
BTZ |
Impairing |
5.0 (High)
|
31955515
|
acc2420 |
Beclin-1 |
ubiquitination |
Ser96 |
human |
Myeloma |
RPMI8226 |
BTZ |
Impairing |
5.0 (High)
|
31955515
|
acc2421 |
MRE11 |
ubiquitination |
Lys339 |
human |
Breast Cancer |
HCC1806 |
Radiotherapy |
Enhancing |
5.0 (High)
|
36563124
|
acc2422 |
MRE11 |
ubiquitination |
Lys339 |
human |
Breast Cancer |
MDA-MB-231 |
Radiotherapy |
Enhancing |
5.0 (High)
|
36563124
|
acc2423 |
MRE11 |
ubiquitination |
Lys480 |
human |
Breast Cancer |
HCC1806 |
Radiotherapy |
Enhancing |
5.0 (High)
|
36563124
|
acc2424 |
MRE11 |
ubiquitination |
Lys480 |
human |
Breast Cancer |
MDA-MB-231 |
Radiotherapy |
Enhancing |
5.0 (High)
|
36563124
|
acc2425 |
RIPK1 |
ubiquitination |
unclear |
human |
Leukemia |
MT4 |
Birinapant |
Associated |
4.0 (Moderate) |
32024820
|
acc2426 |
CYLD |
phosphorylation |
Ser418 |
human |
Leukemia |
MT4 |
Birinapant |
Associated |
4.0 (Moderate) |
32024820
|
acc2427 |
RIPK1 |
ubiquitination |
unclear |
human |
Leukemia |
MT4 |
MRT67307 |
Associated |
4.0 (Moderate) |
32024820
|
acc2428 |
CYLD |
phosphorylation |
Ser418 |
human |
Leukemia |
MT4 |
MRT67307 |
Associated |
4.0 (Moderate) |
32024820
|
acc2429 |
RIPK1 |
ubiquitination |
unclear |
human |
Leukemia |
MT4 |
TPCA |
Associated |
4.0 (Moderate) |
32024820
|
acc2430 |
CYLD |
phosphorylation |
Ser418 |
human |
Leukemia |
MT4 |
TPCA |
Associated |
4.0 (Moderate) |
32024820
|
acc2431 |
ERK1 |
phosphorylation |
Thr202 |
human |
Hepatocellular Carcinoma |
Hep3B |
EGCG |
Associated |
4.0 (Moderate) |
19360302
|
acc2432 |
ERK1 |
phosphorylation |
Tyr204 |
human |
Hepatocellular Carcinoma |
Hep3B |
EGCG |
Associated |
4.0 (Moderate) |
19360302
|
acc2433 |
ERK2 |
phosphorylation |
Thr185 |
human |
Hepatocellular Carcinoma |
Hep3B |
EGCG |
Associated |
4.0 (Moderate) |
19360302
|
acc2434 |
ERK2 |
phosphorylation |
Tyr187 |
human |
Hepatocellular Carcinoma |
Hep3B |
EGCG |
Associated |
4.0 (Moderate) |
19360302
|
acc2435 |
NFKBIA |
phosphorylation |
Ser32 |
human |
Myeloma |
MM.1S |
PS-1145 |
Associated |
4.0 (Moderate) |
11872748
|
acc2436 |
NFKBIA |
phosphorylation |
Ser32 |
human |
Myeloma |
RPMI8226 |
PS-1145 |
Associated |
4.0 (Moderate) |
11872748
|
acc2437 |
NFKBIA |
phosphorylation |
Ser32 |
human |
Myeloma |
U266 |
PS-1145 |
Associated |
4.0 (Moderate) |
11872748
|
acc2438 |
NFKBIA |
phosphorylation |
Ser32 |
human |
Myeloma |
MM.1S |
PS-1145 + Dex |
Associated |
4.0 (Moderate) |
11872748
|
acc2439 |
TOPK |
phosphorylation |
Thr9 |
human |
Melanoma |
RPMI7951 |
arsenite |
Associated |
4.0 (Moderate) |
17145805
|
acc2440 |
H2AX |
phosphorylation |
Ser139 |
human |
Melanoma |
RPMI7951 |
arsenite |
Associated |
3.0 (Low)
|
17145805
|
acc2441 |
AMPK |
phosphorylation |
Thr172 |
human |
Lung Cancer |
A549 |
TRAIL |
Impairing |
5.0 (High)
|
29929000
|
acc2442 |
AMPK |
phosphorylation |
Thr183 |
human |
Lung Cancer |
A549 |
TRAIL |
Impairing |
5.0 (High)
|
29929000
|
acc2443 |
AMPK |
phosphorylation |
Thr172 |
human |
Lung Cancer |
HCC-15 |
TRAIL |
Impairing |
5.0 (High)
|
29929000
|
acc2444 |
AMPK |
phosphorylation |
Thr183 |
human |
Lung Cancer |
HCC-15 |
TRAIL |
Impairing |
5.0 (High)
|
29929000
|
acc2445 |
JNK2 |
phosphorylation |
Thr183 |
human |
Colorectal Cancer |
HT29 |
TRAIL + 5-fluorouracil (5-FU) |
Enhancing |
5.0 (High)
|
15837763
|
acc2446 |
JNK2 |
phosphorylation |
Thr183 |
human |
Hepatocellular Carcinoma |
HepG2 |
TRAIL + 5-fluorouracil (5-FU) |
Enhancing |
5.0 (High)
|
15837763
|
acc2447 |
JNK2 |
phosphorylation |
Tyr185 |
human |
Colorectal Cancer |
HT29 |
TRAIL + 5-fluorouracil (5-FU) |
Enhancing |
5.0 (High)
|
15837763
|
acc2448 |
JNK2 |
phosphorylation |
Tyr185 |
human |
Hepatocellular Carcinoma |
HepG2 |
TRAIL + 5-fluorouracil (5-FU) |
Enhancing |
5.0 (High)
|
15837763
|
acc2449 |
JNK2 |
phosphorylation |
Thr183 |
human |
Colorectal Cancer |
HT29 |
TRAIL + Cisplatin |
Enhancing |
5.0 (High)
|
15837763
|
acc2450 |
JNK2 |
phosphorylation |
Thr183 |
human |
Hepatocellular Carcinoma |
HepG2 |
TRAIL + Cisplatin |
Enhancing |
5.0 (High)
|
15837763
|